MARY OAKS: Open Payments
NPI 1588143150 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$676 in 33 payments from 11 companies in 2025. Trend: 2023 $274 · 2024 $530 · 2025 $676
Food & beverage: $664Education: $12
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $162 |
| Novo Nordisk Inc | 6 | $149 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $142 |
| Gilead Sciences, Inc. | 4 | $68 |
| Edwards Lifesciences Corporation | 1 | $30 |
| SANOFI-AVENTIS U.S. LLC | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $18 |
Products named: MOUNJARO, Kerendia, Rybelsus, SAPIEN 3 Ultra RESILIA, TZIELD, Ozempic, Symbravo, Dexcom G6 Transmitter.
Industry payments across KY — which companies pay providers there.
